NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
7 Hills Pharma, LLC
AstraZeneca
Bristol-Myers Squibb
PrECOG, LLC.
TCR2 Therapeutics
Oslo University Hospital
The Netherlands Cancer Institute